Response to Ipilimumab and Nivolumab in a Patient With Malignant Peritoneal Mesothelioma.Published in:Clinical Colorectal Cancer, 2022, v. 21, n. 4, p. 371, doi. 10.1016/j.clcc.2022.08.001By:Rizzolo, Angelo;Kenny Chia Ah-Lan;Tuyet Nhung Ton Nu;Alcindor, ThierryPublication type:Article